Allergy Therapeutics Plc Positive data with house-dust mite immunotherapy

Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today announced positive new data on its wholly-owned modified house-dust mite subcutaneous immunotherapy1. This data will be presented today at the 37th Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) in Munich, Germany.

The Group’s modified house-dust mite product sold as through a Named Patient Program in Spain, is the precursor to the modified house-dust mite + MPL product currently in Phase I, as announced in February 2017.

In this observational study conducted in 10 sites across Spain, 141 patients were evaluated and demonstrated a 43% decrease in combined symptom medication score compared with baseline after one year (p = <0.0001). In addition, in a subgroup of asthmatic subjects, 16.7% of patients were observed with moderate persistent asthma at one year compared with 50.9% at baseline (p = <0.01). No patients presented with serious adverse events and no patients had to stop treatment due to any adverse event.

Allergy Therapeutics also presented a series of poster presentations at EAACI with key highlights including an overview of the early-phase pre-clinical developments for the Group’s planned recombinant peanut vaccine3 and a discussion of the results of a non-interventional study investigating rapid up-dosing of tree sublingual immunotherapy4.

Other events held by the Group at EAACI included a satellite symposium entitled: “Adjuvants through the ages”2 which provided a summary of how adjuvant technologies have evolved and how Allergy Therapeutics is spearheading the design and testing of state of the art allergen-specific immunotherapies.

Manuel Llobet, Allergy Therapeutics plc Chief Executive Officer, commented: “We are excited to be sharing our latest research at EAACI, demonstrating the breadth of our unique allergen immunotherapy company. The positive new data on our modified house-dust mite immunotherapy and our recent announcement on the success of our Grass G205 dose-finding clinical study confirms that our novel allergen-specific immunotherapies are formulated to the optimal strength, and we believe Allergy Therapeutics has the potential to transform allergy treatment with optimised-dose, well-characterised, aluminium-free, convenient products.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
X
LinkedIn
Allergy therapeutics plc

More articles like this

Allergens dominate UK food recalls, finds study

More than half of food recalls in the United Kingdom over a 5-year period were due to allergens, according to a recently released study. Allergen-related recalls increased annually until 2019, peaking at 118 before decreasing to

Allergy Therapeutics welcomes new Non-Executive Directors

Allergy Therapeutics announced the appointments of Anthony Parker and Simon Shen to its Board as Non-Executive Directors effective immediately. “I would like to welcome Anthony and Simon. Southern Fox and ZQ Capital have been long-standing and supportive shareholders of Allergy

Allergy Therapeutics updates on its clinical programmes

Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has announced that the first subject has been dosed in the pivotal Phase III G306 trial, to evaluate the efficacy and safety of

Allergy Therapeutics appoints two Non-Executive Directors

Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has today announced the appointments of Anthony Parker and Zheqing (Simon) Shen as Non-Executive Directors of the Company, with immediate effect. Anthony represents

Allergies and Thanksgiving

As Thanksgiving and other holiday celebrations bring people around the table, Intermountain Healthcare dietitians say it’s crucial to take food allergies into consideration when planning the big meal. “A response to an allergic reaction can be

Allergy Therapeutics appoints Martin Hopcroft as interim CFO

Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has announced the appointment of Martin Hopcroft to the role of Interim Chief Financial Officer (CFO). Martin will report into Chief Executive

Food business operator fined for allergy breach

A food business operator based in Newcastle, England has been fined in court after serving a dish containing peanuts to a woman with a peanut allergy, resulting in her being hospitalised. According to the Food Standards

Are restaurants taking allergies seriously?

In an engaging panel held at Twickenham Stadium as part of New Food’s Food Safety Conference 2022, experts came together to debate whether food allergy regulations in restaurants are sufficient. Here’s the highlights. Are restaurant allergy

Allergy Therapeutics Subscription to raise £7 million

Allergy Therapeutics plc (LON:AGY), the fully integrated specialty pharmaceutical company specialising in allergy immunotherapy, today announces a conditional Subscription by the Subscribers, Southern Fox and ZQ Capital (acting through its affiliate SkyGem), to raise £7 million